Who is sponsoring NCT04627129?

NCT04627129 is sponsored by Jiangsu HengRui Medicine Co., Ltd..

What drugs are being tested in NCT04627129?

Interventions in NCT04627129: SHR2554 and Itraconazole.

What condition does NCT04627129 study?

NCT04627129 studies Healthy Adult Subjects.

Is NCT04627129 still recruiting?

NCT04627129 is currently completed. Last updated 13 November 2020.

Last reviewed 2020-11-13 · How we verify

NCT04627129

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Itraconazole Effect Study of SHR2554 on Healthy Chinese Adult Subjects

Completed Phase 1 Last updated 13 November 2020

What this trial tests

Phase 1 trial testing SHR2554 and Itraconazole in Healthy Adult Subjects in 18 participants. Completed in 1 October 2020.

Timeline

1 June 2020

Primary endpoint
1 October 2020

1 October 2020

Quick facts

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	18
Start date	1 June 2020
Primary completion	1 October 2020
Estimated completion	1 October 2020
Sites	1 location across China

Drugs / interventions tested

SHR2554 and Itraconazole — full drug profile →

Conditions studied

Healthy Adult Subjects — all drugs for Healthy Adult Subjects →

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

Adults 18 to 45, any sex, with Healthy Adult Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the study is to evaluate the effect of Itraconazole on pharmacokinetics of healthy Chinese adult subjects after oral administration of SHR2554 tablets. The secondary objective of the study is to evaluate the safety of single dose of SHR2554 orally in healthy subjects.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0
The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1.
Fledderus J, Vanchin B, Rots MG, Krenning G. · · 2021 · cited 19× · PMID 33562658 · DOI 10.3390/jpm11020103
Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial.
Deng K, Zou Y, Zou C, Wang H, et al · · 2023 · cited 6× · PMID 35841331 · DOI 10.1002/cam4.5028

Verify or expand the search:

Other recruiting trials for Healthy Adult Subjects

Currently open trials in the same condition.

NCT06635226 — Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects · Phase 1 · recruiting

Other Jiangsu HengRui Medicine Co., Ltd. trials

Trials by the same sponsor.

NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04627129 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
Last refreshed: 13 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04627129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing